Get started
Author

Isabel Prieto González-Albo

Observed name: Isabel Prieto Gonzalez-Albo
OpenAlex ID: A5032720171
Yippee like 4 (Ypel4) is essential for normal mouse red blood cell membrane integrity
2021 · Alexander Mattebo, Taha Sen, et al. · Scientific Reports · 13
PDF
A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
2023 · Danny N. Khalil, Isabel Prieto González-Albo, et al. · Investigational New Drugs · 10
PDF
Englumafusp alfa plus glofitamab in B cell non-Hodgkin lymphoma: a phase 1 trial
2026 · Martin Hutchings, Michael Dickinson, et al. · Nature Medicine · 4
PDF
FORTITUDE: Results of a phase 1a study of the novel transgene-armed and tumor-selective vector NG-350A with and without pembrolizumab (pembro).
2022 · Lee S. Rosen, D. Ross Camidge, et al. · Journal of Clinical Oncology · 2
CD19-CD28 costimulatory bispecific antibody plus glofitamab in R/R B-NHL: a phase 1 dose-escalation study
2026 · Michael J. Dickinson, Koorosh Korfi, et al. · Blood Advances
ABCL-736: Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study
2026 · Dok Hyun Yoon, David Berz, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-736: Outpatient Treatment With Glofitamab Plus Gemcitabine and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety Results From a Phase 2 Study
2026 · Dok Hyun Yoon, David Berz, et al. · Clinical Lymphoma Myeloma & Leukemia
Correction to: A tumor-selective adenoviral vector platform induces transient antiphospholipid antibodies, without increased risk of thrombosis, in phase 1 clinical studies
2023 · Danny N. Khalil, Isabel Prieto González-Albo, et al. · Investigational New Drugs
PDF
Safety and tolerability of T-SIGn vectors when administered using “flat” versus “low-high-high” (LHH) dosing regimens.
2022 · Thomas Lillie, Lee S. Rosen, et al. · Journal of Clinical Oncology
A proteomic approach to study the molecular processes of a novel putative zinc binding protein in erythropoiesis
2017 · Isabel Prieto González-Albo
Works count: 10
Citation count: 29
H-index: 3
I10-index: 2
Year
Topic
Type